<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Mi sitio]]></title><description><![CDATA[My Site 3]]></description><link>https://www.lmt.law/blog</link><generator>RSS for Node</generator><lastBuildDate>Wed, 03 Jun 2026 18:31:00 GMT</lastBuildDate><atom:link href="https://www.lmt.law/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[PATENTES Y ESTRATEGIA DE NEGOCIOS]]></title><description><![CDATA[1. ¿Cuándo vale la pena patentar una innovación farmacéutica?]]></description><link>https://www.lmt.law/post/patentes-y-estrategia-de-negocios</link><guid isPermaLink="false">6a1f77d6f9e37e2aaa1524b7</guid><pubDate>Wed, 03 Jun 2026 00:40:48 GMT</pubDate><dc:creator>Kath LR</dc:creator></item></channel></rss>